Semaglutide Trial on Obese Patients With Insulin Resistance Completed

A clinical trial evaluating semaglutide has reached completed status as of October 2, 2026. The study, registered as NCT06856291, is titled "Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance." According to the trial registry, the study status is listed as completed. No phase was specified for this trial in the available record. The trial focused on non-diabetic obese patients and examined responses across varying degrees of insulin resistance, per the study title. Semaglutide is an approved compound, and this trial represents one of the ongoing lines of clinical research involving the drug. No results have been reported in connection with this update, and no outcome data accompany the completed status designation. Readers should note that a completed status refers only to the trial reaching its concluding stage, not to the availability or content of findings. Further details about study design, enrollment, or endpoints were not included in this event record. For additional context on semaglutide, including its approved uses and other research activity, readers can consult the compound overview.